- Home
- KYMR vs MKTX Comparison
KYMR vs MKTX Comparison
Compare KYMR & MKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | KYMR | MKTX |
|---|---|---|
| Founded | 2015 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Investment Bankers/Brokers/Service |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.8B | 6.0B |
| IPO Year | 2020 | 2004 |
Fundamental Metrics
Financial Performance| Metric | KYMR | MKTX |
|---|---|---|
| Price | $80.62 | $178.91 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 26 | 9 |
| Target Price | $107.72 | ★ $204.38 |
| AVG Volume (30 Days) | ★ 627.8K | 424.5K |
| Earning Date | 05-18-2026 | 05-11-2026 |
| Dividend Yield | N/A | ★ 1.75% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 6.64 |
| Revenue | $39,211,000.00 | ★ $397,471,000.00 |
| Revenue This Year | $16.05 | $10.06 |
| Revenue Next Year | $4.79 | $7.20 |
| P/E Ratio | ★ N/A | $27.09 |
| Revenue Growth | N/A | ★ 7.45 |
| 52 Week Low | $19.45 | $156.17 |
| 52 Week High | $103.00 | $232.84 |
Technical Indicators
Market Signals| Indicator | KYMR | MKTX |
|---|---|---|
| Relative Strength Index (RSI) | 47.12 | 46.67 |
| Support Level | $77.78 | $177.38 |
| Resistance Level | $95.90 | $183.23 |
| Average True Range (ATR) | 4.42 | 4.63 |
| MACD | -1.27 | -1.27 |
| Stochastic Oscillator | 23.04 | 16.13 |
Price Performance
Historical ComparisonAbout KYMR Kymera Therapeutics Inc.
Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of differentiated medicines that address health problems and meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, TYK2, and IRAK4.
About MKTX MarketAxess Holdings Inc.
Founded in 2000, MarketAxess is a leading electronic fixed-income trading platform that connects broker/dealers and institutional investors. The company is primarily focused on credit based fixed income securities with its main trading products being US investment-grade and high-yield bonds, Eurobonds, and Emerging Market corporate debt. Recently the company has expanded more aggressively into Treasuries and municipal bonds with the acquisitions of LiquidityEdge and MuniBrokers in 2019 and 2021, respectively. The company also provides pre- and post-trade services with its acquisition of Regulatory Reporting Hub from Deutsche Börse Group in 2020 adding to its product offerings.